Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer
Donglin Liu(Boston University), Chien‐Hsing Chang(Immunomedics (United States)), David M. Goldenberg(Unknown), Thomas M. Cardillo(Immunomedics (United States)), Yang Wang(Dalian Medical University), Edmund A. Rossi(Immunomedics (United States))
Cited by 33
Related Papers
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
|New England Journal of Medicine|2019|846
Allelic reprogramming of 3D chromatin architecture during early mammalian development
|Nature|2017|559
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
|Oncotarget|2015|464